Document:

EX-10.18

 Exhibit 10.18 
  

 
 GENOMIC AND PROTEOMIC SERVICES AGREEMENT 

This Genomic and Proteomic Services Agreement (the “Agreement”) is entered into effective as of this 18th day of
June, 2015 by and between Conkwest, Inc. (“Customer”) and NantOmics, LLC (“NantOmics”). 
 RECITALS 

WHEREAS, Customer is engaged in development of novel cancer treatments and therapies; 

WHEREAS, NantOmics is engaged in the provision of genomic and proteomic analysis and bioinformatics services; and 

WHEREAS, Customer desires to receive NantOmics’ services in connection with the performance of clinical trials for its
cancer treatments and therapies (including to identify potential clinical trial candidates for such treatments and therapies). 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
agree as follows: 
 AGREEMENT 

1.      DESCRIPTION OF SERVICES. 

1.1    Provision of Services.    NantOmics agrees to perform whole genome
sequencing (WGS), whole exome sequencing (WES), RNA-Seq and proteomic analyses services, and related computational, data management and bioinformatics services, as requested from time to time by Customer and agreed by NantOmics, in accordance with
and subject to the terms and conditions set forth in this Agreement and provided that the applicable samples provided to NantOmics are adequate for such purpose (the “Services”). NantOmics will use its commercial reasonable efforts to
provide the Services in a timely, skillful, professional and workmanlike manner by qualified personnel exercising care, skill and diligence consistent with industry standards, and in accordance with the terms and conditions of this Agreement.
Customer acknowledges that Service turnaround times are dependent upon and subject to resource and capacity commitments at the time that Services are requested. For the avoidance of doubt, NantOmics shall furnish the facilities, equipment,
instruments, supplies, personnel and other resources reasonably necessary for the performance of the Services. 

1.2    Samples.  In order to enable NantOmics to perform the Services, Customer shall
provide, or cause to be provided, tissue and blood samples in such quantities as are reasonably required to perform the Services. Preparation, packaging and shipping of samples shall be performed in accordance with NantOmics procedures and
protocols. 

  
 1 

 

 
  

1.3    Customer Cooperation.    Customer’s timely provision of accurate
information, data and cooperation (collectively “Cooperation”) is essential to NantOmics’s performance of its obligations under this Agreement and NantOmics shall not be liable for any deficiency, delay or failure in performing its
obligations if such deficiency, delay or failure results from Customer’s failure to provide such Cooperation. 

1.4    Exclusivity.    During the term of this Agreement and except to the
extent otherwise agreed by the parties on a case-by-case basis, NantOmics will be the exclusive provider of genomic and proteomic analysis services, and related computational, data management and bioinformatics services, to Customer and its
subsidiaries and, accordingly, Customer and its subsidiaries agree that they will not procure such services from another provider. 

2.      COMPENSATION.    As compensation for the Services, Customer shall pay
NantOmics according to the fee schedule set forth on Exhibit A. NantOmics shall invoice Customer monthly for Services performed during the preceding month, according to the fee schedule set forth on Exhibit A. Invoices are
due and payable within thirty (30) days of receipt by Customer. Payment shall be delivered to NantOmics at the address set forth on each invoice. 

3.      TERM AND TERMINATION.    The term of this Agreement shall commence on the
effective date set forth above and continue for a term of five (5) years. Thereafter, the term of this Agreement will automatically renew for additional successive one (1) periods terms unless and until this Agreement is terminated in
accordance with this Section 3. This Agreement may be terminated by either party in the event of a material default by the other, provided that written notice of such default and the intent to terminate has been given to the defaulting party
and such default has not been remedied to the reasonable satisfaction of the non-defaulting party within thirty (30) days of delivery of such notice. In addition, either party may terminate this Agreement for any reason upon ninety (90)
days prior written notice to the other party; provided that if NantOmics terminates this Agreement for convenience in accordance with the foregoing, then NantOmics shall still remain obligated to perform Services for those clinical trials it agreed
to provide Services for prior to termination. Upon expiration of this Agreement or termination by either Party, in addition to amounts accruing hereunder for Services already completed, Customer shall also be liable to NantOmics for Services then in
process, but completed after the date of expiration or termination, provided that the Services were initiated prior to the effective date of expiration or termination, at the rate set forth on Exhibit A. 

4.      RESULTS, NANTOMICS PLATFORM.    Customer may utilize the data and information
produced and reported by NantOmics from the provision of Services (the “Results”) in connection with the performance of clinical trials for the cancer treatment and/or therapy for which the Services were performed (including for the
purpose of identifying potential clinical trial candidates for such treatment or therapy). Customer 

  
 2 

 

 
  
 
agrees that NantOmics retains and shall own all right, title and interest in and to the NantOmics Platform, Results (including the right to publish findings resulting from the Services) and any
computer programs, software, documentation, copyrightable work, discoveries, inventions or improvements developed or made by NantOmics solely, or with others, in connection with the Services. The “NantOmics Platform” means the hardware,
software, systems, tools, database processes, reporting methodology, testing procedures and other technology utilized by or for NantOmics in the operation or provision of Services. 

5.      CONFIDENTIALITY. 

5.1      Confidential Information.    “Confidential
Information” means any non-public, proprietary or confidential information or material of a Party that (i) is disclosed in writing and is clearly marked as “confidential” or with a similar proprietary notice at the time of
disclosure; (ii) is disclosed verbally and identified as “confidential” or similarly at the time of disclosure, or (iii) by its nature, a reasonable person would consider confidential. If Confidential Information is disclosed or
otherwise made available by a party (the “Disclosing Party”) to the other party (the “Receiving Party”), the Receiving Party shall use such Confidential Information only for the purpose for which it was provided or as otherwise
agreed to in writing and not disclose such Confidential Information to any person or entity (except to its affiliates and contractors that are bound by written nondisclosure agreements or obligations as least as protective as the terms and
conditions of this Section 5). The terms and conditions of this Agreement shall be Confidential Information of both parties and disclosure of all or any part thereof to any third party or the public shall be upon consent of both parties hereto.

 5.2      Exceptions.    This Section 5 shall not apply to
Confidential Information that: (i) becomes publicly available through no fault of the Receiving Party; (ii) is or becomes available to the Receiving Party or its affiliates on a non-confidential basis from a third party; provided, that
such third party is not and was not prohibited from disclosing the Confidential Information; (iii) was already known by or in the possession of the Receiving Party or its affiliates; (iv) is independently developed or received by the
Receiving Party or its affiliates without reference to or use of the Disclosing Party’s Confidential Information; or (v) is subject to disclosure by law, legal requirement, regulation, judicial process or order, in which case, if permitted
by law, the Receiving Party shall use reasonable efforts to provide written notice to the Disclosing Party of its obligation to disclose such Confidential Information with an opportunity to seek for the Disclosing Party to object. 

5.3      Business Associate Agreement.    If and to the extent
required under the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, as may be amended from time to time (“HIPAA”), the parties shall enter into an industry standard business associate agreement
covering the use and protection of any Protected Health Information (as such term is defined under HIPAA (the “BAA”). 

  
 3 

 

 
  
 
However, notwithstanding anything to the contrary in this Agreement or the BAA, (i) Customer hereby grants to NantOmics a non-exclusive, non-transferable right and license to use the
information, data and other content provided to NantOmics in connection with the Services for the purpose of performing NantOmics’s obligations hereunder; (ii) NantOmics may use, analyze and disclose Protected Health Information:
(a) for the health care operations and billing of Customer, NantOmics and their Affiliates, (b) as otherwise permitted under HIPAA (including to perform data aggregation and for the public health activities and purposes described in 45
C.F.R. § 164.512(b)), and/or (c) as otherwise permitted under applicable patient consents/authorizations; and (iii) NantOmics may de-identify Protected Health Information and/or create “Limited Data Sets” in accordance with
45 C.F.R. § 164.514. Customer acknowledges and agrees that de-identified information is not Protected Health Information and that NantOmics may use such de-identified information for any lawful purpose. 

6.      RELATIONSHIP OF THE PARTIES.    In performing the Services, NantOmics is
acting as an independent contractor. In no event shall this Agreement be construed as establishing a partnership or joint venture or similar relationship between the parties hereto, and nothing herein contained shall be construed to authorize either
party to act as agent for the other. 
 7.      INSURANCE, INDEMNIFICATION AND LIMITATION OF LIABILITY.

 7.1      Insurance.    Throughout the term of this Agreement,
each of the parties shall secure and maintain, where appropriate, commercial general liability insurance, professional liability insurance, property insurance, workers compensation insurance, and such other insurance coverage or properly reserved
self insurance, in such forms and amounts as may be reasonable and appropriate in the performance of the obligations assumed hereunder. Upon request, each party shall provide the other with certificates of proof of the insurance coverage required
herein. 
 7.2      Indemnification.    Each party (the
“Indemnifying Party”) agrees to defend the other party and its parent and affiliates and their respective directors, officers, employees, agents or contractors, and all of such persons’ successors and assigns (collectively, the
“Indemnified Persons”), from and against any and all third party claims, and indemnify and hold the Indemnified Persons harmless from and against any and all damages finally awarded the third party claimant, to the extent such claim is a
result of a violation of applicable law by the Indemnifying Party, negligence or willful misconduct of the Indemnifying Party (including any personal injury, death, or damage to tangible personal or real property) or, in the case of indemnification
by Customer, use or exploitation of the Results or any diagnosis, treatment, prescription of medication or any other medical service or decision relating to Customer or any of its treatments or therapies, provided that: (i) the Indemnifying
Party is promptly notified of the claim in writing (but the failure of Indemnified Persons to promptly provide notice shall not relieve the Indemnifying Party of its indemnification obligations hereunder except to the

  
 4 

 

 
  
 
extent materially prejudiced thereby); (ii) the Indemnifying Party is given full control of the defense and settlement of the matter; (iii) the Indemnified Persons cooperate fully with
the Indemnifying Party in the defense and settlement of the matter. 
 7.3      Limitation
of Liability.    The cumulative, aggregate liability of NantOmics in connection with this Agreement will not exceed the total amount of all fees paid and payable to NantOmics under this Agreement during the twelve month
period preceding the applicable claim. In no event will either party be liable for lost profits or any special, indirect, incidental, exemplary, consequential, indirect or punitive damages arising in connection with this Agreement, regardless of
whether such party has been notified of the potential for such damages, or whether such damages were reasonably foreseeable, or whether any claim for recovery is based on theories of contract, tort, or otherwise. 

8.      REPRESENTATIONS AND WARRANTIES. 

8.1      Mutual Representations and Warranties.    Each party
represents and warrants to the other Party that: (a) it is duly formed, validly existing, and in good standing under the laws of its jurisdiction of formation; (b) its execution of this Agreement has been duly authorized by all necessary
action of such party; (c) when executed and delivered by it, this Agreement will constitute its legal, valid, and binding obligation, enforceable against it in accordance with its terms; (d) its execution, delivery, and performance of its
obligations under this Agreement does not and will not violate any judgment, order, decree, or applicable law, nor does it or will it violate any agreement to which it is a party; and (e) it have not been: (i) debarred under the provisions
of the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335a(a) or any other U.S. Federal or State law or regulation; (ii) disqualified as a testing facility under the provisions of 21 C.F.R. Part 58, Subpart K; (iii) convicted of
any crime relating to any federal and/or state program; or (iv) included in the Specially Designated Nationals list (“SDN List”) maintained by the U.S. Department of Treasury’s Office of Foreign Assets Control or any other
similar list, domestic or foreign. 

8.2      Disclaimer.    EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH
IN THIS AGREEMENT, EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, WITH RESPECT TO THIS AGREEMENT OR ANY SUBJECT MATTER HEREOF. THE SERVICES AND RESULTS SHALL NOT BE USED TO FUNCTION AS, OR REPLACE, ANY
MEDICAL TREATMENT, EXAMINATION, DIAGNOSIS OR OTHER MEDICAL PRACTICE, PROCEDURE, DEVICE OR SERVICE. UNDER NO CIRCUMSTANCES SHOULD CUSTOMER OR ANY OTHER PARTY RELY SOLELY ON THE INFORMATION PRESENTED ON OR VIA THE SERVICES OR RESULTS TO PERFORM
THERAPEUTIC OR DIAGNOSTIC PROCEDURES OR ACTIONS, TO MAKE DIAGNOSES, OR TO TAKE ANY OTHER DECISION OR CONSEQUENTIAL ACTION. 

  
 5 

 

 
  

9.      AUDIT RIGHTS AND RECORD KEEPING.    Throughout the term of this Agreement and
for a period of five (5) years following the expiration or termination hereof, Customer, or any of its duly authorized representatives shall, upon reasonable notice and during normal business hours, have access to and the right to audit, at its
own expense, NantOmics’s laboratory facilities, documents or records, which pertain specifically to compliance with quality standards, regulatory requirements, or other obligations relating to the performance of the Services under this
Agreement. All documents or records pertaining to NantOmics’s performance of any obligation under this Agreement shall be retained by NantOmics throughout the term of this Agreement and for a period of five (5) years following the
termination or expiration hereof. 
 10.      COMPLIANCE WITH LAWS AND
REGULATIONS.    Each of the parties shall perform their respective obligations in compliance with all applicable federal, state and local laws, regulations, ordinances and safety codes, including but not limited to all
laboratory licensing requirements and all regulations regarding patient safety and confidentiality. 

11.      USE OF TRADEMARKS.    Neither party shall use the name or any trademark of
the other in any advertising, marketing, letterhead, sales promotion, publicity, or for any other purpose without the prior written approval of the other. Notwithstanding the foregoing, Customer consents to NantOmics including Customer’s name,
location and publicly available logo in NantOmics promotional materials that list NantOmics’s customers (provided such list does not include any attribution of any endorsement to Customer). 

12.      GENERAL PROVISIONS. 

12.1      Notices.    All notices required to be in writing shall be
deemed to have been given either at the time of delivery if delivered personally or by an independent contract carrier; or twenty-four (24) hours after the time of postmark if mailed Express Mail, postage prepaid, return receipt requested, or
three (3) days after the time of postmark if mailed registered or certified mail, postage prepaid, return receipt requested, and in each case, addressed as set forth below: 

To NantOmics: 

NantOmics, LLC 

9920 Jefferson Boulevard 

Culver City, California 90232 

Attn: Chief Executive Officer 

To Customer: 

Conkwest, Inc. 

  
 6 

 

 
  
 2533 S. Coast Hwy.
101, Suite 210 
 Cardiff, CA 92007 

Attn: President 

or to such other address as any party shall designate at any time in writing by notice to the other party in accordance with this paragraph.

 12.2      Governing Law.    This Agreement shall be interpreted
and construed in accordance with the laws of the State of California, without application of any principles of choice of laws. 

12.3      Nonwaiver.    A waiver by either party of any breach of
this Agreement shall not be binding upon the waiving party unless such waiver is in writing. In the event of a written waiver, such a waiver shall not affect the waiving party’s rights with respect to any other or further breach. 

12.4      Execution by Counterpart.    This Agreement may be executed
separately or independently in any number of counterparts, by original or facsimile signature, each and all of which together shall be deemed to have been executed simultaneously and for all purposes to be one Agreement. 

12.5      Section Headings.    The section and subsection headings in
this Agreement are included for convenience only and shall not in any way effect the interpretation or construction of any provision hereof. 

12.6      Force Majeure.    If by reason of labor disputes, strikes,
lockouts, embargo, riots, war, inability to obtain labor, materials or transportation facilities, earthquake, fire or other action of the elements, accidents, governmental restrictions, appropriation, compliance with any law, regulation or other
governmental order or any other causes beyond the control of a party hereto, either party is unable to perform in whole or in part its obligations as set forth in this Agreement, excluding any obligations to make payments hereunder, then such party
will be relieved of those obligations to the extent it is so unable to perform and such inability to perform will not make such party liable to the other party. Neither party will be liable for any losses, injury, delay or damages suffered or
incurred by the other party due to the above causes. 
 12.7      Entire Agreement;
Successors in Interest; Assignment.    This Agreement contains the entire Agreement of the parties with respect to the subject matter hereof. This Agreement shall be binding upon and inure to the benefit of the successors and
assigns of the parties. Neither party may assign or otherwise transfer this Agreement or any of its rights under this Agreement, in each case whether voluntarily or involuntarily, without the other party’s prior written consent, which will not
be unreasonably withheld, conditioned, or delayed; provided, however, that either party may assign this Agreement to a party that obtains all or substantially all of the assigning parties assets to which this

  
 7 

 

 
  
 
Agreement relates. Any assignment or other transfer without such prior written consent will be null and void. NantOmics may subcontract its obligations under this Agreement to a third party,
provided that NantOmics informs Customer prior to using any material subcontractor that is not a NantOmics affiliate and NantOmics will remain responsible to Customer for any performance of its obligations hereunder notwithstanding the permitted
engagement of any such third party. 

  
 8 

 

 
  
 IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the dates set forth above. 
 NANTOMICS, LLC 

(“NantOmics”) 
 By:
    /s/ Charles Kim                               

Name:     Charles
Kim                             

Title:     General
Counsel                           

CONKWEST, INC. 

(“Customer”) 
 By:
    /s/ Barry J. Simon                          

Name:     Barry J.
Simon                         

Title:
    President                                   
  

  
 9 

 

 
  
 EXHIBIT A 

Service Pricing 
  

			
	 $12,500 per sample
		 Whole genome sequencing (WGS), whole exome sequencing (WES) and RNA-Seq services and related computational, data management and bioinformatics
services

		
	 $7,200 per sample
		 Proteomic analyses services

  
 10Exhibit
4.4

 

YULONG
ECO-MATERIALS LIMITED

 

FORM
OF WARRANT AGREEMENT

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
SUCH ACT.

 

This
certifies that, for good and valuable consideration, receipt of which is hereby acknowledged, Axiom Capital Management, Inc. (“Holder”)
is entitled to purchase, subject to the terms and conditions of this Warrant, from Yulong Eco-Materials Limited, an exempted company
with limited liability under the laws of Cayman Islands (the “Company”), [•] Ordinary Shares, par value
$0.00125 per share (the “Ordinary Shares”) of the Company, in accordance with Section 2 hereof during the period
commencing on [•], 2015 (the “Commencement Date”) and ending at 5:00 P.M. New York time, [•], 2020
(the “Expiration Date”), at which time this Warrant will expire and become void unless earlier terminated as
provided herein. The Ordinary Shares of the Company for which this Warrant is exercisable, as adjusted from time to time pursuant
to the terms hereof, are hereinafter referred to as the “Ordinary Shares” or “Shares.”

 

1.     Exercise
Price. The initial purchase price for the Ordinary Shares shall be $[•] per share. Such price shall be subject to
adjustment pursuant to the terms hereof (such price, as adjusted from time to time, is hereinafter referred to as the “Exercise
Price”).

 

2.     Exercise
and Payment.

 

(a)     Cash
Exercise. At any time after the Commencement Date, this Warrant may be exercised, in whole or in part, from time to time
by the Holder, during the term hereof, by surrender of this Warrant and the Notice of Exercise annexed hereto duly completed and
executed by the Holder to the Company at the principal executive offices of the Company, together with payment in the amount obtained
by multiplying the Exercise Price then in effect by the number of Shares thereby purchased, as designated in the Notice of Exercise.
Payment may be in cash or by check payable to the order of the Company.

 

(b)     Net
Issuance. In lieu of payment of the Exercise Price described in Section 2(a), the Holder may elect to receive, without
the payment by the Holder of any additional consideration, Shares equal to the value of this Warrant or any portion hereof by
the surrender of this Warrant or such portion to the Company, with the net issue election notice annexed hereto (the “Net
Issuance Election”) duly executed, at the principal executive offices of the Company. Thereupon, the Company shall issue
to the Holder such number of Ordinary Shares as is computed using the following formula:

 

	where:  	X = Y 	(A-B)	 
	   A	 

   

    	 

    	 

    

 

X
= the number of Shares to be issued to the Holder pursuant to this Section 2(b).

 

Y
= the number of Shares covered by this Warrant in respect of which the net issuance election is made pursuant to this Section
2(b).

 

A
= the fair market value of one (1) Ordinary Share, as determined in accordance with the provisions of this Section 2(b).

 

B
= the Exercise Price in effect under this Warrant at the time the net issuance election is made pursuant to this Section 2(b).

 

For
purposes of this Section 2(b), the “fair market value” per Ordinary Share shall mean:

 

(i)     If
the Ordinary Shares are traded on a national securities exchange or other over-the-counter quotation system, the fair market value
shall be the last reported sale price of the Ordinary Shares on such national securities exchange or other over-the-counter quotation
system on the last business day before the effective date of exercise of the Net Issuance Election or if no such sale is made
on such day, the mean of the closing bid and asked prices such day on such national securities exchange or other over-the-counter
quotation system; and

 

(ii)     If
the Ordinary Shares are not so listed or admitted to unlisted trading privileges and bid and ask prices are not reported, the
fair market value shall be the price per Ordinary Share which the Company could obtain from a willing buyer for Ordinary Shares
sold by the Company for authorized but unissued Ordinary Shares, as such price shall be determined by mutual agreement of the
Company and the Holder of this Warrant.

 

3.     Reservation
of Shares. The Company hereby agrees that at all times during the term of this Warrant there shall be reserved for issuance
and delivery upon exercise of this Warrant such number of Ordinary Shares or other shares of capital stock of the Company from
time to time issuable upon exercise of this Warrant. All such Ordinary Shares, upon issuance, shall be free and clear of all liens,
security interests, charges and other encumbrances or restrictions on sale and free and clear of all preemptive rights. The Company
covenants and agrees that, upon exercise of the Warrant and payment of the Exercise Price therefor, in accordance with the terms
hereby, all Ordinary Shares and other securities issuable upon such exercise shall be duly and validly issued, fully paid and
non-assessable and not subject to preemptive rights of any stockholder. As long as the Warrant shall be outstanding, the Company
shall use its best efforts to cause the Ordinary Shares to be listed on The NASDAQ Capital Market and to maintain such listings.

 

4.     Delivery
of Certificates. Within a reasonable time after exercise, in whole or in part, of this Warrant, the Company shall issue
in the name of and deliver to the Holder a certificate or certificates for the number of Ordinary Shares which the Holder shall
have requested in the Notice of Exercise or Net Issuance Election, as applicable. If this Warrant is exercised in part, the Company
shall deliver to the Holder a new Warrant for the unexercised portion of this Warrant at the time of delivery of such certificate
or certificates.

 

5.     No
Fractional Shares. No fractional Shares or scrip representing fractional Shares will be issued upon exercise of this Warrant.
If upon any exercise of this Warrant a fraction of a Share results, the Company will pay the Holder the difference between the
cash value of the fractional Share and the portion of the Exercise Price allocable to the fractional Share.

 

    	- 2 -

    	 

    

 

6.     Listing.
Prior to the issuance of any Ordinary Shares upon exercise of this Warrant, the Company shall secure the listing of such Ordinary
Shares upon each national securities exchange or automated quotation system, if any, upon which Ordinary Shares are then listed
(subject to official notice of issuance upon exercise of this Warrant) and shall maintain, so long as any other Shares shall be
so listed, such listing of all Ordinary Shares from time to time issuable upon the exercise of this Warrant; and the Company shall
so list on each national securities exchange or automated quotation system, and shall maintain such listing of, any other shares
of capital stock of the Company issuable upon the exercise of this Warrant if and so long as any shares of the same class shall
be listed on such national securities exchange or automated quotation system.

 

7.     Charges,
Taxes and Expenses. The Company shall pay all transfer taxes or other incidental charges, if any, in connection with the
transfer of the Shares purchased pursuant to the exercise hereof from the Company to the Holder.

 

8.     Loss,
Theft, Destruction or Mutilation of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of
the loss, theft, destruction or mutilation of this Warrant, and in case of loss, theft or destruction, of indemnity or security
reasonably satisfactory to the Company, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and
upon surrender and cancellation of this Warrant, if mutilated, the Company will make and deliver a new Warrant of like tenor and
dated as of such cancellation, in lieu of this Warrant.

 

9.     Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall be a Saturday or a Sunday or shall be a legal holiday, then such action may be taken or such right may
be exercised on the next succeeding weekday that is not a legal holiday.

 

10.     Adjustment
of Exercise Price and Number of Shares. The Exercise Price and the number of and kind of securities purchasable upon exercise
of this Warrant shall be subject to adjustment from time to time as follows:

 

  (a)     Subdivisions,
Combinations and Other Issuances. If the Company shall at any time after the date hereof but prior to the expiration of
this Warrant subdivide its outstanding securities as to which purchase rights under this Warrant exist, by split-up or otherwise,
or combine its outstanding securities as to which purchase rights under this Warrant exist, the number of Shares as to which this
Warrant is exercisable as of the date of such subdivision, split-up or combination will be proportionately increased in the case
of a subdivision, or proportionately decreased in the case of a combination. Appropriate adjustments also will be made to the
Exercise Price, but the aggregate purchase price payable for the total number of Shares purchasable under this Warrant as of such
date shall remain the same.

 

    	- 3 -

    	 

    

 

(b)     Stock
Dividend. If at any time after the date hereof the Company declares a dividend or other distribution on Ordinary Shares
payable in Ordinary Shares or Convertible Securities without payment of any consideration by such holder for the additional Ordinary
Shares or the Convertible Securities (including the additional Ordinary Shares issuable pursuant to the terms thereof), then the
number of Ordinary Shares for which this Warrant may be exercised shall be increased as of the record date (or the date of such
dividend distribution if no record date is set) for determining which holders of Ordinary Shares shall be entitled to receive
such dividend, in proportion to the increase in the number of outstanding Ordinary Shares (and Ordinary Shares issuable pursuant
to the terms of the Convertible Securities) as a result of such dividend, and the Exercise Price shall be adjusted so that the
aggregate amount payable for the purchase of all the Shares issuable hereunder immediately after the record date (or on the date
of such distribution, if applicable) for such dividend will equal the aggregate amount so payable immediately before such record
date (or on the date of such distribution, if applicable). As used herein, “Convertible Securities” means evidences
of indebtedness, shares of capital stock or other securities which are convertible into or exchangeable for, with or without payment
of additional consideration, Ordinary Shares, either immediately or upon the arrival of a specified date or the happening of a
specified event or both.

 

(c)     Other
Distributions. If at any time after the date hereof the Company distributes to holders of its Ordinary Shares, other than
as part of its dissolution or liquidation or the winding up of its affairs, any shares of its capital stock, any evidence of indebtedness
or any of its assets (other than cash, Ordinary Shares or Convertible Securities), then the Company shall, at its option, either
(i) decrease the Exercise Price of this Warrant by an appropriate amount based upon the value distributed on each Ordinary Share
as determined in good faith by the Company’s board of directors or (ii) provide by resolution of the Company’s board
of directors that on exercise of this Warrant, the Holder hereof shall thereafter be entitled to receive, in addition to the Shares
otherwise receivable on exercise hereof, the number of Ordinary Shares or other securities or property which would have been received
had this Warrant at the time been exercised.

 

(d)     Merger.
If at any time after the date hereof there shall be a merger or consolidation of the Company with or into another corporation
when the Company is not the surviving corporation, then the Holder shall thereafter be entitled to receive upon exercise of this
Warrant, during the period specified herein and upon payment of the aggregate Exercise Price then in effect, the number of Shares
or other securities or property of the successor corporation resulting from such merger or consolidation, which would have been
received by Holder for the Shares subject to this Warrant had this Warrant been exercised at such time.

 

(e)     Reclassification,
Etc. If at any time after the date hereof there shall be a change or reclassification of the securities as to which purchase
rights under this Warrant exist into the same or a different number of securities of any other class or classes, then the Holder
shall thereafter be entitled to receive upon exercise of this Warrant, during the period specified herein and upon payment of
the Exercise Price then in effect, the number of shares or other securities or property resulting from such change or reclassification,
which would have been received by Holder for the Shares subject to this Warrant had this Warrant been exercised at such time.

 

    	- 4 -

    	 

    

  

(f)     Certain
Issuances of Securities. Except as expressly provided in subsections (b) and (c) of this Section 10, if the Company issues
any Additional Stock for no consideration or for a consideration per share less than the Exercise Price in effect immediately prior
to the time of such issuance, then the Exercise Price shall be reduced to the price determined by dividing:

 

(i)     an
amount equal to the sum of (x) the number of Ordinary Shares outstanding immediately prior to such issuance or sale multiplied
by the then existing Exercise Price, and (y) an amount equal to the aggregate “consideration actually received” by
the Company upon such issuance or sale, by

 

(ii)     the
sum of the number of Ordinary Shares outstanding immediately after such issuance or sale.

 

Upon any adjustment of the Exercise Price under
this subsection (f) of this Section 10, the number of Ordinary Shares issuable upon exercise of this Warrant shall equal the number
of shares determined by dividing (x) the aggregate Exercise Price payable for the purchase of all shares issuable upon exercise
of this Warrant immediately prior to such adjustment by (y) the Exercise Price per share in effect immediately after such adjustment.

 

For purposes of adjusting the Exercise Price
pursuant to this Section 10(f):

 

(A)The
term “Additional Stock” shall mean any Ordinary Shares, Convertible Securities or Options issued by the Company
after the Commencement Date, other than (1) Ordinary Shares issuable upon the conversion of Convertible Securities issued by the
Company before the Commencement Date, (2) Options issued by the Company to any of its officers, directors, employees, consultants
or agents after the Commencement Date pursuant to any compensation or benefit plan approved by the Company’s board of directors
or, if not pursuant to such a plan, then pursuant to any other resolution of the Company’s board of directors, in each case
at the fair market value thereof as determined in accordance with Section 2, on the date of the Option grant, (3) Ordinary Shares
issuable upon the exercise of Options issued by the Company to any of its officers, directors, employees, consultants or agents
before, on or after the Commencement Date pursuant to any compensation or benefit plan approved by the Company’s board of
directors or, if not pursuant to such a plan, then pursuant to any other resolution of the Company’s board of directors,
in each case, at the fair market value thereof, as determined in accordance with Section 2, on the date of the Option grant, and
(4) Ordinary Shares issued in connection with the purchase of assets or businesses, whether by merger, consolidation, purchase
of assets or stock or otherwise. As used herein, the term “Option” means any right, warrant, or option to subscribe
for or purchase Ordinary Shares or Convertible Securities.

 

(B)In
the case of an issuance or sale for cash of Ordinary Shares, the “consideration actually received” by the Company therefor
shall be deemed to be the amount of cash received, before deducting therefrom any commissions or expenses paid by the Company.

 

    	- 5 -

    	 

    

 

(C)In
the case of the issuance (other than upon conversion or exchange of obligations or shares of stock of the Company) of Ordinary
Shares for a consideration other than cash or a consideration partly other than cash, the amount of the non-cash “consideration
actually received” by the Company shall be deemed to be the fair market value of such consideration as determined in good
faith by the Company’s board of directors.

 

(D)In
the case of the issuance by the Company in any manner of Options, all Ordinary Shares or Convertible Securities to which the holders
of such Options shall be entitled to subscribe for or purchase pursuant to such Options shall be deemed issued as of the date of
the grant or sale of such Options, and the minimum aggregate consideration named in such Options for the Ordinary Shares or Convertible
Securities covered thereby, plus the consideration, if any, received by the Company for such Options, shall be deemed to be the
“consideration actually received” by the Company (as of the date of the granting or sale of such Options) for the issuance
of such Options.

 

(E)In
the case of the issuance by the Company in any matter of Convertible Securities, all Ordinary Shares issuable upon the conversion
or exchange of such Convertible Securities shall be deemed issued as of the date such Convertible Securities are issued, and the
amount of the “consideration actually received” by the Company for such Convertible Securities shall be deemed to be
the total of (1) the amount of consideration received by the Company upon the issuance of such Convertible Securities, plus (2)
the minimum aggregate consideration, if any, other than such Convertible Securities, receivable by the Company upon conversion
or exchange of such Convertible Securities, except in adjustment of dividends.

 

(F)The
amount of “consideration actually received” by the Company upon the issuance of any Options referred to in subparagraph
(D) above or upon the issuance of Convertible Securities as described in subparagraph (E) above, and the amount of the consideration,
if any, other than Convertible Securities, receivable by the Company upon exercise, conversion, or exchange thereof shall be determined
in the same manner provided in subparagraphs (B) and (C) above with respect to the consideration received by the Company in the
case of the issuance of additional Ordinary Shares; provided, however, that if such Convertible Securities are issued in payment
or satisfaction of any dividend upon any stock of the Company other than Ordinary Shares, the amount of the “consideration
actually received” by the Company upon the original issuance of such Convertible Securities shall be deemed to be the value
of such obligations or shares of stock, as of the date of the adoption of the resolution declaring such dividend, as reasonably
determined in good faith by the Company’s board of directors at or as of that date.

 

(G)On
the expiration of any Options referred to in subparagraph (D) above, or the termination of any right of conversion with respect
to Convertible Securities referred to in subparagraph (E) above, or any change in the number of Ordinary Shares deliverable upon
the exercise of such Options or upon conversion or exchange of such Convertible Securities, the Exercise Price then in effect shall
be adjusted to such Exercise Price as would have been obtained had the adjustments made upon the issuance of such Options or Convertible
Securities been made upon the basis of the delivery of the adjusted number of Ordinary Shares actually delivered or to be delivered
upon the exercise of such Options or upon the conversion or exchange of such Convertible Securities.

 

    	- 6 -

    	 

    

 

11.     Notice
of Adjustments; Notices. Whenever the Exercise Price or number of Shares purchasable hereunder is adjusted pursuant to
Section 10 hereof, the Company must execute and deliver to the Holder a certificate setting forth, in reasonable detail, the event
requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated and the Exercise Price
and number of and kind of securities purchasable hereunder after giving effect to such adjustment, and must cause a copy of such
certificate to be mailed (by first class mail, postage prepaid) to the Holder.

 

12.     Rights
As Stockholder; Notice to Holders. Nothing contained in this Warrant will be construed as conferring upon the Holder or
his or its permitted transferees the right to vote or to receive dividends or to consent or to receive notice as a shareholder
in respect of any meeting of shareholders for the election of directors of the Company or of any other matter, or any rights whatsoever
as shareholders of the Company. The Company will notify the Warrant Holder by registered mail if at any time prior to the expiration
or exercise in full of the Warrant, any of the following events occur:

 

  (a)     a
dissolution, liquidation or winding up of the Company shall be proposed;

 

  (b)     a
capital reorganization or reclassification of the Ordinary Shares (other than a subdivision or combination of the outstanding
Ordinary Shares and other than a change in the par value of the Ordinary Shares) or any consolidation or merger of the Company
with or into another corporation (other than a consolidation or merger in which the Company is the continuing corporation and
that does not result in any reclassification or change of Ordinary Shares outstanding) or in the case of any sale or conveyance
to another corporation of the property of the Company as an entirety or substantially as an entirety; or

 

  (c)     a
taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof
who are entitled to receive any dividend (other than a cash dividend) or other distribution, any right to subscribe for, purchase
or otherwise acquire any shares of stock of any class or any other securities or property, or to receive any other rights.

 

  (d)     an
issuance by the Company of any Additional Stock, as defined in subsection (f) of Section 10.

 

Such
giving of notice will be simultaneous with the giving of notice to holders of Ordinary Shares. Such notice must specify the record
date or the date of closing the stock transfer books, as the case may be. Failure to provide such notice will not affect the validity
of any action taken in connection with such dividend, distribution or subscription rights, or proposed merger, consolidation,
sale, conveyance, dissolution, liquidation or winding up.

 

    	- 7 -

    	 

    

 

13.     Restricted
Securities. The Holder understands that if a Registration Statement is not in effect to register this Warrant, the Ordinary
Shares issuable upon exercise of this Warrant, this Warrant and, subject to the last sentence of this Section 13, the Shares purchasable
hereunder will constitute “restricted securities” under the federal securities laws inasmuch as they are, or will
be, acquired from the Company in transactions not involving a public offering and accordingly may not, under such laws and applicable
regulations, be resold or transferred without registration under the Securities Act of 1933, as amended (the “1933 Act”),
or an applicable exemption from such registration. If a Registration Statement is not in effect, or the Company’s Ordinary
Shares are not registered for trading on a national exchange, then, at the election of the Holder, this Warrant may be exercised
for Ordinary Shares of the Company. If a Registration Statement is not in effect, unless the Shares are subsequently registered
pursuant to Section 16 of this Warrant, the Holder further acknowledges that the securities legend on Exhibit A to the Notice
of Exercise attached hereto shall be placed on any Shares issued to the Holder upon exercise of this Warrant. Notwithstanding
the foregoing, if a Holder exercises a net issuance under Section 2(b), the Shares will be deemed to be purchased under Section
3(a)(9) of the 1933 Act and will not be “restricted securities” or subject to legend if the Warrant has been held
for a period of one (1) year or more.

 

14.     Certification
of Investment Purpose. Unless a current registration statement under the 1933 Act shall be in effect with respect to the
securities to be issued upon exercise of this Warrant, the Holder covenants and agrees that, at the time of exercise hereof, it
will deliver to the Company a written certification executed by the Holder that the securities acquired by him upon exercise hereof
are for the account of such Holder and acquired for investment purposes only and that such securities are not acquired with a
view to, or for sale in connection with, any distribution thereof.

 

15.     Disposition
of Shares; Transferability.

 

  (a)     Holder
hereby agrees not to make any disposition of any Warrants purchased hereunder unless and until:

 

    (i)     Holder
shall have notified the Company of the proposed disposition and provided a written summary of the terms and conditions of the
proposed disposition; and

 

    (ii)     Holder
shall have complied with all requirements of this Warrant applicable to the disposition of the Warrant.

 

The
Company shall not be required (i) to transfer on its books any Warrants which have been sold or transferred in violation of the
provisions of this Section 15 or (ii) to treat as the owner of the Warrants, or otherwise to accord voting or dividend rights
to, any transferee to whom the Shares have been transferred in contravention of the terms of this Warrant.

 

  (b)     Transfer.
This Warrant shall be transferable only on the books of the Company maintained at its principal office in Eastern End of Xiwuzhuang
Village, Jiaodian Town, Xinhua Area, Pingdingshan, Henan Province, the People’s Republic of China, or wherever its principal
office may then be located, upon delivery thereof duly endorsed by the Holder or by its duly authorized attorney or representative,
accompanied by proper evidence of succession, assignment or authority to transfer. Upon any registration of transfer, the Company
shall execute and deliver new Warrants to the person entitled thereto.

 

    	- 8 -

    	 

    

 

  (c)     Limitations
on Transfer. This Warrant and Ordinary Shares issuable upon exercise hereof may not be sold, transferred, assigned, pledged,
or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective
economic disposition of such securities (any such action, a “Transfer”) by any person for a period of one hundred
eighty (180) days immediately following the date of effectiveness or commencement of sales of the public offering of the Ordinary
Shares, except in accordance with Financial Industry Regulatory Authority (“FINRA”) Rule 5110(g)(2). This Warrant
may be divided or combined, upon request to the Company by the Holder, into a certificate or certificates representing the right
to purchase the same aggregate number of Shares. If at the time of a Transfer, a Registration Statement is not in effect to register
this Warrant, the Company may require the Holder to make such representations, and may place such legends on certificates representing
this Warrant, as may be reasonably required in the opinion of counsel to the Company to permit a Transfer without such registration.

 

16.     Registration
Rights.

 

  (a)     Demand
Registration. The Company, upon written demand (a “Demand Notice”) of the Holder, agrees to register,
on one occasion, all or any portion of the Registrable Securities (as defined below). On such occasion, the Company will file
a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt of a Demand
Notice and use its reasonable best efforts to have the registration statement declared effective promptly thereafter, subject
to compliance with review by the Commission; provided, however, that the Company shall not be required to comply with a Demand
Notice if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback registration
rights pursuant to Section 16(b) hereof and either: (i) the Holder has elected to participate in the offering covered by such
registration statement or (ii) if such registration statement relates to an underwritten primary offering of securities of the
Company, until the offering covered by such registration statement has been withdrawn or until thirty (30) days after such offering
is consummated. The demand for registration may be made at any time during a period of five (5) years beginning on the Commencement
Date. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holders to all other
registered Holders of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any
such Demand Notice.

 

  (b)     Piggyback
Registration. If at any time prior to the Expiration Date a Registration Statement is not in effect to register this Warrant
and the Ordinary Shares issuable upon exercise of this Warrant, the Company determines to register for its own account or the
account of others under the 1933 Act any of its equity securities, other than on Form S-4 or Form S-8 or their then equivalents
relating to equity securities to be issued solely in connection with any acquisition of any entity or business, or equity securities
issuable in connection with stock option or other employee benefit plans, the Company shall send to each Holder of Warrants or
Shares written notice of such determination and, if within twenty (20) days after receipt of such notice, such Holder shall so
request in writing (hereafter a “Selling Holder”), the Company shall use commercially reasonable efforts to
include in such Registration Statement all or any part of the Shares issuable or issued upon exercise of the Warrants (the “Registrable
Securities”) such Selling Holder requests to be registered. The obligations of the Company under this Section 16(b)
may be waived by Holders holding a majority in interest of the Registrable Securities. In the event that the managing underwriter
for an offering advises the Company in writing that the inclusion of such securities in the offering would be materially detrimental
to the offering, such securities shall nevertheless be included in the Registration Statement, provided that the Holder and each
holder of Shares desiring to have their Shares included in the Registration Statement agree in writing, for a period of ninety
(90) days following such offering, not to sell or otherwise dispose of such Shares pursuant to such Registration Statement, which
Registration Statement the Company shall keep updated and effective for a period of at least nine (9) months following the expiration
of such (ninety) 90-day period.

 

    	- 9 -

    	 

    

 

(c)     Obligations
of the Holders. In connection with the registration of the Registrable Securities pursuant to either Sections 16(a) or
(b), the Selling Holders shall have the following obligations:

 

  (i)     It
shall be a condition precedent to the obligations of the Company to take any action pursuant to this Agreement with respect to
each Selling Holder that such Selling Holder shall furnish to the Company such information regarding itself, the Registrable Securities
held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to
effect the registration of the Registrable Securities and shall execute such documents in connection with such registration as
the Company may reasonably request. At least fifteen (15) days prior to the first anticipated filing date of the Registration
Statement the Company shall notify each Selling Holder of the information the Company requires from each such Selling Holder (the
“Requested Information”) in the case of a Registration Statement being prepared pursuant to Section 16(b) or
if such Selling Holder elects to have any of such Selling Holder’s Registrable Securities included in the Registration Statement
in the case of a Registration Statement being prepared pursuant to Section 16(a).

 

  (ii)     Each
Selling Holder by such Selling Holder’s acceptance of the Registrable Securities agrees to cooperate with the Company as
reasonably requested by the Company in connection with the preparation and filing of the Registration Statement hereunder, unless
such Selling Holder has notified the Company in writing of such Selling Holder’s election to exclude all of such Selling
Holder’s Registrable Securities from the Registration Statement; and

 

  (iii)     No
Selling Holder may participate in any underwritten registration hereunder unless such Selling Holder (i) agrees to sell such Selling
Holder’s Registrable Securities on the basis provided in any underwriting arrangements approved by the Selling Holders entitled
hereunder to approve such arrangements, (ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting
agreements and other documents reasonably required under the terms of such underwriting arrangements, and (iii) agrees to pay
its pro rata share of all underwriting discounts and commissions and other fees and expenses of investment bankers and any manager
or managers of such underwriting, except as provided in Section 16(e) below.

 

(d)     Obligations
of the Company. If and whenever the Company is required to use its best efforts to take action pursuant to any Federal
or state law or regulation to permit the sale or other disposition of any Shares purchasable upon exercise of this Warrant that
are then held or that may be acquired upon exercise of the Warrants in order to effect or cause the registration of any Registrable
Securities under the 1933 Act as provided in this Section 16, the Company shall, as expeditiously as practicable:

 

    	- 10 -

    	 

    

 

(i)     prepare
and file with the SEC, as soon as practicable within ninety (90) days after the end of the period within which requests for registration
may be given to the Company a Registration Statement or Registration Statements relating to the registration on any appropriate
form under the 1933 Act, which form shall be available for the sale of the Registrable Securities in accordance with the intended
method or methods of distribution thereof, and use its best efforts to cause such Registration Statements to become effective;
provided that before filing a Registration Statement or Prospectus or any amendment or supplements thereto, including documents
incorporated by reference after the initial filing of any Registration Statement, the Company will furnish to the Holders of the
Registrable Securities covered by such Registration Statement and the underwriters, if any, copies of all such documents provided
to be filed, which documents will be subject to the review of such Holders and underwriters;

 

(ii)     prepare
and file with the SEC such amendments and post-effective amendments to a Registration Statement as may be necessary to keep such
Registration Statement effective for a reasonable period or as otherwise provided herein; cause the related Prospectus to be supplemented
by any required Prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 under the 1933 Act; and comply
with the provisions of the 1933 Act with respect to the disposition of all securities covered by such Registration Statement during
such period in accordance with the intended methods of disposition by the sellers thereof set forth in such Registration Statement
or supplement to such Prospectus;

 

(iii)     notify
the selling Holders of Registrable Securities and the managing underwriters, if any, promptly, and (if requested by any such Person)
confirm such advice in writing, (A) when a Prospectus or any Prospectus supplement or post-effective amendment has been filed,
and, with respect to a Registration Statement or any post-effective amendment, when the same has become effective; (B) of any
request by the SEC for amendments or supplements to a Registration Statement or related Prospectus or for additional information;
(C) of the issuance by the SEC of any stop order suspending the effectiveness of a Registration Statement or the initiation of
any proceedings for that purpose; (D) if at any time the representations and warranties of the Company contemplated by paragraph
(xiv) below ceases to be true and correct in all material respects; (E) of the receipt by the Company of any notification with
respect to the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction or the initiation
or threatening of any proceeding for such purpose; and (F) of the happening of any event that makes any statement of a material
fact made in the Registration Statement, the Prospectus or any document incorporated therein by reference untrue or which requires
the making of any changes in the Registration Statement or Prospectus so that they will not contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not
misleading;

 

(iv)     make
every reasonable effort to obtain the withdrawal of any order suspending the effectiveness of a Registration Statement at the
earliest possible moment;

 

(v)     if
reasonably requested by the managing underwriters, immediately incorporate in a Prospectus supplement or post-effective amendment
such information as the managing underwriters believe (on advice of counsel) should be included therein as required by applicable
law relating to such sale of Registrable Securities, including, without limitation, information with respect to the purchase price
being paid for the Registrable Securities by such underwriters and with respect to any other terms of the underwritten (or “best-efforts”
underwritten) offering; and make all required filings of such Prospectus supplement or post-effective amendment as soon as notified
of the matters to be incorporated in such Prospectus supplement or post-effective amendment;

 

    	- 11 -

    	 

    

 

(vi)     furnish
to each selling Holder of Registrable Securities and each managing underwriter, without charge, at least one (1) signed copy of
the Registration Statement and any post-effective amendment thereto, including financial statements and schedules, all documents
incorporated therein by reference and all exhibits (including those incorporated by reference);

 

(vii)     deliver
to each selling Holder of Registrable Securities and the underwriters, if any, without charge, as many copies of the Prospectus
or Prospectuses (including each preliminary Prospectus) any amendment or supplement thereto as such Persons may reasonably request;
the Company consents to the use of such Prospectus or any amendment or supplement thereto by each of the selling Holders of Registrable
Securities and the underwriters, if any, in connection with the offering and sale of the Registrable Securities covered by such
Prospectus or any Amendment or supplement thereto;

 

(viii)     prior
to any public offering of Registrable Securities, cooperate with the selling Holders of Registrable Securities, the underwriters,
if any, and their respective counsel in connection with the registration or qualification of such Registrable Securities for offer
and sale under the securities or Blue Sky laws of such jurisdictions within the United States as any selling Holder or underwriter
reasonably requests in writing, keep each such registration or qualification effective during the period such Registration Statement
is required to be kept effective and do any and all other acts or things necessary or advisable to enable the disposition in such
jurisdictions of the Registrable Securities covered by the applicable Registration Statement; provided that the Company will not
be required to qualify to do business in any jurisdiction where it is not then so qualified or to take any action which would
subject the Company to general service of process in any jurisdiction where it is not at the time so subject;

 

(ix)     cooperate
with the selling Holders of Registrable Securities and the managing underwriters, if any, to facilitate the timely preparation
and delivery of certificates representing Registrable Securities to be sold and not bearing any restrictive legends; and enable
such Registrable Securities to be in such denominations and registered in such names as the managing underwriters may request
at least two (2) Business Days prior to any sale of Registrable Securities to the underwriters;

 

(x)     use
its best efforts to cause the Registrable Securities covered by the applicable Registration Statement to be registered with or
approved by such other governmental agencies or authorities within the United States as may be necessary to enable the seller
or sellers thereof or the underwriters, if any, to consummate the disposition of such Registrable Securities;

 

(xi)     upon
the occurrence of any event contemplated by Section 16(d)(iii)(F) above, prepare a supplement or post-effective amendment to the
applicable Registration Statement or related Prospectus or any document incorporated therein by reference or file any other required
document so that, as thereafter delivered to the purchasers of the Registrable Securities being sold thereunder, such Prospectus
will not contain an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein
not misleading;

 

    	- 12 -

    	 

    

 

(xii)     with
respect to each issue or class of Registrable Securities, use its best efforts to cause all Registrable Securities covered by
the Registration Statements to be listed on each securities exchange, if any, on which similar securities issued by the Company
are then listed if requested by the Holders of a majority of such issue or class of Registrable Securities;

 

(xiii)     enter
into such agreements (including an underwriting agreement) and take all such other action reasonably required in connection therewith
in order to expedite or facilitate the disposition of such Registrable Securities and in such connection, if the registration
is in connection with an underwritten offering (A) make such representations and warranties to the underwriters, in such form,
substance and scope as are customarily made by issuers to underwriters in underwritten offering and confirm the same if and when
requested; (B) obtain opinions of counsel to the Company and updates thereof (which counsel and opinions in form, scope and substance
shall be reasonably satisfactory to the underwriters and selling Holders of Registrable Securities) addressed to the underwriters
and selling Holders of Registrable Securities covering the matters customarily covered in opinions requested in underwritten offerings
and such other matters as may be reasonably requested by such underwriters and selling Holders of Registrable Securities; (C)
obtain “cold comfort” letters and updates thereof from the Company’s accountants addressed to the underwriters
and selling Holders of Registrable Securities, such letters to be in customary form and covering matters of the type customarily
covered in “cold comfort” letters in connection with underwritten offerings; (D) set forth in full in any underwriting
agreement entered into the indemnification provisions and procedures of Section 16(f) hereof with respect to all parties to be
indemnified pursuant to said Section; and (E) deliver such documents and certificates as may be reasonably requested by the underwriters
to evidence compliance with clause (i) above and with any customary conditions contained in the underwriting agreement or other
agreement entered into by the Company; the above shall be done at each closing under such underwriting or similar agreement or
as and to the extent required hereunder;

 

(xiv)     if
the registration is in connection with a nonunderwritten offering (A) obtain opinions of counsel to the Company and updates thereof
(which counsel and opinions in form, scope and substance shall be reasonably satisfactory to the selling Holders of Registrable
Securities) addressed to the selling Holders of Registrable Securities covering the matters customarily covered in opinions requested
in underwritten offerings and such other matters as may be reasonably requested by such selling Holders of Registrable Securities;
and (B) deliver letters and updates thereof signed by the Chief Financial Officer of the Company and addressed to the selling
Holders of Registrable Securities, such letters certifying the accuracy of financial information included or incorporated in the
Prospectus and covering matters of the type customarily covered in “cold comfort” letters from accountants in connection
with underwritten offerings.

 

    	- 13 -

    	 

    

 

(xv)     make
available for inspection by one (1) or more representatives of the Holders of Registrable Securities being sold, any underwriter
participating in any disposition pursuant to such registration, and any attorney or accountant retained by such Holders or underwriter,
all financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s officers,
directors and employees to supply all information reasonably requested by any such representatives, in connection with such; and

 

(xvi)     otherwise
use its best efforts to comply with all applicable Federal and state regulations; and take such other action as may be reasonably
necessary to or advisable to enable each such Holder and each such underwriter to consummate the sale or disposition in such jurisdiction
or jurisdiction in which any such Holder or underwriter shall have requested that the Registrable Securities be sold.

 

Except
as otherwise provided in this Agreement, the Company shall have sole control in connection with the preparation, filing, withdrawal,
amendment or supplementing of each Registration Statement, the selection of underwriters, and the distribution of any preliminary
prospectus included in the Registration Statement, and may include within the coverage thereof additional Ordinary Shares or other
securities for its own account or for the account of one (1) or more of its other security holders.

 

The
Company may require each Seller of Registrable Securities as to which any registration is being effected to furnish to the Company
such information regarding the distribution of such securities and such other information as may otherwise be required by the
193 3 Act to be included in such Registration Statement.

 

(e)     Expenses
of Registration. All expenses, other than underwriting discounts and commissions and other fees and expenses of investment
bankers and other than brokerage commissions, incurred in connection with registrations, filings or qualifications pursuant to
Section 16(a) or 16(b), including, without limitation, all registration, listing and qualifications fees, printers and accounting
fees and the fees and disbursements of counsel for the Company and the Selling Holders, shall be borne by the Company; provided,
however, that the Company shall only be required to pay the fees and out-of-pocket expenses of one (1) legal counsel selected
by the Selling Holders to represent them in connection with such registration.

 

    	- 14 -

    	 

    

 

(f)     Indemnification.
In the event any Registrable Securities are included in a Registration Statement under this Agreement:

 

 (i)     To
the extent permitted by law, the Company will indemnify and hold harmless each Selling Holder who holds such Registrable Securities,
the directors, if any, of such Selling Holder, the officers, if any, of such Selling Holder, each person, if any, who controls
any Selling Holder within the meaning of the 1933 Act, any underwriter (as defined in the 1933 Act) for the Selling Holders, the
directors, if any, of such underwriter and the officers, if any, of such underwriter, and each person, if any, who controls any
such underwriter within the meaning of the 1933 Act (each, an “Indemnified Person”), against any losses, claims,
damages, expenses or liabilities (joint or several) (collectively, “Claims”) to which any of them may become
subject under the 1933 Act or otherwise, insofar as such Claims (or actions or proceedings, whether commenced or threatened, in
respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement when it first became effective, or any related final prospectus, amendment or supplement thereto,
or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which the statements therein were made, not misleading (a “Violation”).
The Company shall reimburse the Selling Holders and each such underwriter or controlling person, promptly as such expenses are
incurred and are due and payable, for any legal fees or other reasonable expenses incurred by them in connection with investigating
or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained
in this Section 16(f)(i) shall not apply in such case to the extent any such Claim arising out of or based upon a Violation which
occurs in reliance upon and in conformity with information furnished in writing to the Company by any Indemnified Person or underwriter
for such Indemnified Person expressly for use in connection with the preparation of the Registration Statement or any such amendment
thereof or supplement thereto, and shall not apply to amounts paid in settlement of any Claim if such settlement is effected without
the prior written consent of the Company, which consent shall not be unreasonably withheld.

 

 (ii)     In
connection with any Registration Statement in which a Selling Holder is participating, each such Selling Holder agrees to indemnify
and hold harmless, to the same extent and in the same manner set forth in Section 16(f(i), the Company, each of its directors,
each of its officers who signs the Registration Statement, each person, if any, who controls the Company within the meaning of
the 1933 Act, any underwriter and any other stockholder selling securities pursuant to the Registration Statement or any of its
directors or officers or any person who controls such stockholder or underwriter within the meaning of the 1933 Act (collectively
and together with an Indemnified Person, an “Indemnified Party”), against any Claim to which any of them may
become subject, under the 1933 Act or otherwise, insofar as such Claim arises out of or is based upon any Violation, in each case
to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information
furnished to the Company by such Selling Holder expressly for use in connection with such Registration Statement, and such Selling
Holder will reimburse any legal or other expenses reasonably incurred by them in connection with investigating or defending any
such Claim; provided, however, that the indemnity agreement contained in this Section 16(f)(ii) shall not apply to amounts paid
in settlement of any Claim if such settlement is effected without the prior written consent of such Selling Holder, which consent
shall not be unreasonably withheld.

 

 (iii)     Promptly
after receipt by an Indemnified Person or Indemnified Party under this Section 16(f) of notice of the commencement of any action
or proceeding (including any governmental action or investigation), such Indemnified Person or Indemnified Party shall, if a Claim
in respect thereof is made against any indemnifying party under this Section 16(f), deliver to the indemnifying party a written
notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying
party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel
mutually satisfactory to the indemnifying parties; provided, however, that an Indemnified Person or Indemnified Party shall have
the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion
of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party
and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person
or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnifying Party shall pay for
only one (1) separate legal counsel for the Indemnified Parties; such legal counsel shall be selected by the Indemnified Parties
holding a majority in interest of the Registrable Securities. The failure to deliver written notice to the indemnifying party
within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to
the Indemnified Person or Indemnified Party under this Section 16(f), except to the extent that the indemnifying party is prejudiced
in its ability to defend such action. The indemnification required by this Section 16(f) shall be made by periodic payments of
the amount thereof during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and
is due and payable.

 

    	- 15 -

    	 

    

 

 (iv)     Notwithstanding
any of the foregoing, if, in connection with an underwritten public offering of Registrable Securities, the Company, the Selling
Holders and the underwriter(s) enter into an underwriting or purchase agreement relating to such offering which contains provisions
covering indemnification and contribution among the parties, the indemnification and contribution provisions of this Section 16(f)
shall be deemed inoperative for purposes of such offering.

 

(g)     Contribution.
To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make
the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 16(f) to the fullest
extent permitted by law; provided, however, that (i) no contribution shall be made under circumstances where the
maker would not have been liable for indemnification under the fault standards set forth in Section 16(f), (ii) no seller of Registrable
Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution
from any seller of Registrable Securities who was not guilty of such fraudulent misrepresentation, and (iii) contribution by any
seller of Registrable Securities shall be limited in amount to the net amount of proceeds received by such seller from the sale
of such Registrable Securities.

 

(h)     Reports
Under Exchange Act. With a view to making available to the Holders the benefits of Rule 144 promulgated under the 1933
Act or any other similar rule or regulation of the SEC that may at any time permit the Holders to sell securities of the Company
to the public without registration (“Rule 144”), the Company agrees to:

 

  (i)     make
and keep public information available, as those terms are understood and defined in Rule 144; and

 

  (ii)     file
with the SEC in a timely manner all reports and other documents required of the Company under the 1933 Act and the Securities
Exchange Act of 1934, as amended (the “Exchange Act”); and

 

  (iii)     furnish
to each Holder so long as such Holder owns Registrable Securities, promptly upon request, (i) a written statement by the Company
that it has complied with the reporting requirements of Rule 144, (ii) a copy of the most recent annual or quarterly report of
the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably
requested to permit the Holders to sell such securities without registration pursuant to Rule 144.

 

    	- 16 -

    	 

    

  

  (i)     Assignment
of the Registration Rights. The rights to have the Company register Registrable Securities pursuant to this Agreement
shall be automatically assigned by the Holders to transferees or assignees of all or any portion of such securities only if: (i)
the Holder agrees in writing with the transferee or assignee to assign such rights, (ii) the Company is, within a reasonable time
after such transfer or assignment, furnished with written notice of the name and address of such transferee or assignee, (iii)
such assignment is in accordance with and permitted by law and all other agreements between the transferor or assignor and the
Company, including without limitation, stockholder’s agreements, warrants and subscription agreements, and the transferor
or assignor otherwise is not in material default of any obligation to the Company under any such other agreement, and (iv) at
or before the time the Company received the written notice contemplated by clause (ii) of this sentence, the transferee or assignee
agrees in writing with the Company to be bound by all of the provisions contained herein.

 

17.     Miscellaneous.

 

  (a)     Construction.
Unless the context indicates otherwise, the term “Holder” shall include any transferee or transferees of this Warrant
pursuant to Section 15(b), and the term “Warrant” shall include any and all warrants outstanding pursuant to this
Agreement, including those evidenced by a certificate or certificates issued upon division, exchange, substitution or transfer
pursuant to Section 15.

 

  (b)     Restrictions.
By receipt of this Warrant, the Holder makes the same representations with respect to the acquisition of this Warrant as the Holder
is required to make upon the exercise of this Warrant and acquisition of the Shares purchasable hereunder as set forth in the
Form of Investment Letter attached as Exhibit A to the Notice of Exercise attached hereto.

 

  (c)     Notices.
Unless otherwise provided, any notice required or permitted under this Warrant shall be given in writing and shall be deemed effectively
given upon personal delivery to the party to be notified or three (3) days following deposit with the United States Post Office,
by registered or certified mail, postage prepaid and addressed to the party to be notified (or one (1) day following timely deposit
with a reputable overnight courier with next day delivery instructions), or upon confirmation of receipt by the sender of any
notice by facsimile transmission, at the address indicated below or at such other address as such party may designate by ten (10)
days’ advance written notice to the other parties.

 

	 	To Holder:	Axiom Capital Management, Inc.

780 Third Avenue, 43rd Floor

New York, New York 10017
	 	 	 
	 	To the Company:	Eastern End of Xiwuzhuang Village
	 	 	Jiaodian
                                         Town, Xinhua Area
	 	 	Pingdingshan,
                                         Henan Province
	 	 	People’s Republic of China

 

(d)     Governing
Law. This Warrant shall be governed by and construed under the laws of the State of New York as applied to agreements
among New York residents entered into and to be performed entirely within New York.

 

    	- 17 -

    	 

    

 

(e)     Entire
Agreement. This Warrant, the exhibits and schedules hereto, and the documents referred to herein, constitute the entire
agreement and understanding of the parties hereto with respect to the subject matter hereof, and supersede all prior and contemporaneous
agreements and understandings, whether oral or written, between the parties hereto with respect to the subject matter hereof.

 

(f)     Binding
Effect. This Warrant and the various rights and obligations arising hereunder shall inure to the benefit of and be binding
upon the Company and its successors and assigns, and Holder and its successors and assigns.

 

(g)     Waiver;
Consent; Conflicts. This Warrant may not be changed, amended, terminated, augmented, rescinded or discharged (other than
by performance), in whole or in part, except by a writing executed by the parties hereto, and no waiver of any of the provisions
or conditions of this Warrant or any of the rights of a party hereto shall be effective or binding unless such waiver shall be
in writing and signed by the party claimed to have given or consented thereto. Notwithstanding anything to the contrary herein,
in the event of any conflict with the terms of Warrant and any applicable FINRA rule, such FINRA rule shall govern and this Warrant
will be deemed modified to the extent necessary to ensure compliance with such applicable FINRA rule.

 

(h)     Severability.
If one (1) or more provisions of this Warrant are held to be unenforceable under applicable law, such provision shall be excluded
from this Warrant and the balance of the Warrant shall be interpreted as if such provision were so excluded and the balance shall
be enforceable in accordance with its terms.

 

(i)     Counterparts.
This Warrant may be signed in several counterparts, each of which shall constitute an original.

 

    	- 18 -

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Warrant effective as of the date hereof.

 

DATED:
[•], 2015          

 

	 	THE
    COMPANY:
	 	 
	 	YULONG ECO-MATERIALS
    LIMITED
	 	 	 
	 	By:	
	 	Name:	
	 	Its:	
	 	 	 
	 	HOLDER:
	 	 	 
	 	AXIOM CAPITAL MANAGEMENT,
    INC.
	 	 
	 	By:	
	 	Name:	
	 	Its:	

  

 

    	- 19 -

    	 

    

 

NOTICE
OF EXERCISE

 

	To:	Yulong Eco-Materials
    Limited

 

1.     The
undersigned hereby elects to purchase [•] Ordinary Shares of Yulong Eco-Materials Limited, an exempted company with limited
liability under the laws of Cayman Islands (the “Company”) pursuant to the terms of the attached Warrant, and tenders
herewith payment of the purchase price pursuant to the terms of the Warrant.

 

2.     Attached
as Exhibit A is an investment representation letter addressed to the Company and executed by the undersigned as required by Section
14 of the Warrant.

 

3.     Please
issue certificates representing the Ordinary Shares purchased hereunder in the names and in the denominations indicated on Exhibit
A attached hereto.

 

4.     Please
issue a new Warrant for the unexercised portion of the attached Warrant, if any, in the name of the undersigned.

 

	 	Holder:	
	 	 	 
	Dated:
[•]	
	 	 
		By:	
	 	Its:	

 

    	- 20 -

    	 

    

 

NET
ISSUANCE ELECTION NOTICE

 

To:
Yulong Eco-Materials Limited     Date: [•]

 

The
undersigned hereby elects under Section 2 of the attached Warrant to surrender the right to purchase [•] Ordinary Shares
pursuant to the attached Warrant. The Certificate(s) for the shares issuable upon such net issuance election shall be issued in
the name of the undersigned or as otherwise indicated below.

 

Signature:

 

Name
for Registration:

 

Mailing
Address:

 

    	- 21 -

    	 

    

 

EXHIBIT
A

 

LEGEND

 

THIS
WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS WARRANT
MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT AND APPLICABLE
STATE SECURITIES LAWS OR AN OPINION OF COUNSEL ACCEPTABLE TO YULONG ECO-MATERIALS LIMITED THAT SUCH REGISTRATION IS NOT REQUIRED.

 

 

- 22 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]